Patents by Inventor Dennis S. Charney
Dennis S. Charney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240105310Abstract: Provided are systems, methods, and devices for implementing a corresponding intervention treatment regimen for the respective subject. A corresponding first plurality of responses of the respective subject is received when provided a first questionnaire, which is applied to a set of models to determine a baseline resilience. A corresponding interactive digital journal associated with the respective subject is generated, allowing access to a corresponding intervention treatment regimen. The corresponding interactive digital journal charts a progress through the intervention treatment regimen by capturing a corresponding subjective narration and a corresponding objective feedback based on a corresponding second plurality of responses of the respective subject when provided a second questionnaire during exposure to the respective intervention treatment regimen. The corresponding intervention treatment regimen includes a corresponding plurality of curricula.Type: ApplicationFiled: January 26, 2022Publication date: March 28, 2024Inventors: Jonathan M. DEPIERRO, Dennis S. CHARNEY, Vanshdeep SHARMA, Craig L. KATZ, Deborah B. MARIN
-
Publication number: 20230381118Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder.Type: ApplicationFiled: August 7, 2023Publication date: November 30, 2023Inventors: Dennis S. Charney, Adriana Feder
-
Patent number: 11771661Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.Type: GrantFiled: November 5, 2019Date of Patent: October 3, 2023Assignee: Icahn School of Medicine at Mount SinaiInventors: Dennis S. Charney, Adriana Feder
-
Publication number: 20220249605Abstract: The present disclosure provides compositions and formulations containing neuropeptide Y and methods of their use for the treatment of mood and anxiety disorders.Type: ApplicationFiled: April 27, 2022Publication date: August 11, 2022Inventors: Dennis S Charney, James Murrough
-
Patent number: 10898131Abstract: Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image subsets, each consisting of N expression images. Upon completion of the display of each respective subset, the user is challenged as to whether the first and the last images in the respective subset exhibit the same emotion. A score is determined for the respective subset based on whether the subject learned to respond correctly. The number of images in each subset is adjusted to a new number based on these scores. A treatment regimen is prescribed to the subject for the psychiatric disorder based at least in part on the scores.Type: GrantFiled: November 13, 2018Date of Patent: January 26, 2021Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Brian M. Iacoviello, Dennis S. Charney
-
Publication number: 20200253894Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: April 9, 2020Publication date: August 13, 2020Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
-
Publication number: 20200147006Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.Type: ApplicationFiled: November 5, 2019Publication date: May 14, 2020Inventors: Dennis S. Charney, Adriana Feder
-
Patent number: 10478405Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.Type: GrantFiled: December 18, 2015Date of Patent: November 19, 2019Assignee: Icahn School of Medicine at Mount SinaiInventors: Dennis S. Charney, Adriana Feder
-
Publication number: 20190076087Abstract: Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image subsets, each consisting of N expression images. Upon completion of the display of each respective subset, the user is challenged as to whether the first and the last images in the respective subset exhibit the same emotion. A score is determined for the respective subset based on whether the subject learned to respond correctly. The number of images in each subset is adjusted to a new number based on these scores. A treatment regimen is prescribed to the subject for the psychiatric disorder based at least in part on the scores.Type: ApplicationFiled: November 13, 2018Publication date: March 14, 2019Inventors: Brian M. Iacoviello, Dennis S. Charney
-
Patent number: 10123737Abstract: Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image subsets, each consisting of N expression images. Upon completion of the display of each respective subset, the user is challenged as to whether the first and the last images in the respective subset exhibit the same emotion. A score is determined for the respective subset based on whether the subject learned to respond correctly. The number of images in each subset is adjusted to a new number based on these scores. A treatment regimen is prescribed to the subject for the psychiatric disorder based at least in part on the scores.Type: GrantFiled: September 23, 2015Date of Patent: November 13, 2018Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Brian M. Iacoviello, Dennis S. Charney
-
Publication number: 20180015054Abstract: Disclosed herein is method for maintaining the anti-depressant effect of ketamine by administering lithium to patients that respond to ketamine treatment.Type: ApplicationFiled: December 28, 2015Publication date: January 18, 2018Inventors: Dennis S. Charney, James Murrough
-
Publication number: 20170303851Abstract: Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image subsets, each consisting of N expression images. Upon completion of the display of each respective subset, the user is challenged as to whether the first and the last images in the respective subset exhibit the same emotion. A score is determined for the respective subset based on whether the subject learned to respond correctly. The number of images in each subset is adjusted to a new number based on these scores. A treatment regimen is prescribed to the subject for the psychiatric disorder based at least in part on the scores.Type: ApplicationFiled: September 23, 2015Publication date: October 26, 2017Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Brian M. Iacoviello, Dennis S. Charney
-
Publication number: 20170181966Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: January 27, 2017Publication date: June 29, 2017Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20170151191Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: December 14, 2016Publication date: June 1, 2017Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
-
Patent number: 9592207Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: GrantFiled: June 17, 2014Date of Patent: March 14, 2017Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human ServicesInventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Patent number: 9539220Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: GrantFiled: March 5, 2014Date of Patent: January 10, 2017Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human ServicesInventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
-
Publication number: 20160106808Abstract: As follows from the Background section, above, there is a need in the art for improved methods for the treatment of mood and/or anxiety disorders. The present disclosure provides therapeutic agents and methods for treating mood (e.g., Major Depressive Disorder) and anxiety disorders (e.g., OCD, PTSD). In certain aspects, the present disclosure provides a method for treating a human patient for a mood or anxiety disorder, which comprises intranasally administering to a human patient in need of such treatment a composition comprising a therapeutically effective amount of neuropeptide Y (NPY) for reducing or eliminating the symptoms (or one more of the symptoms) of the mood or anxiety disorder.Type: ApplicationFiled: May 13, 2014Publication date: April 21, 2016Inventors: Dennis S Charney, James Murrough
-
Publication number: 20160101069Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.Type: ApplicationFiled: December 18, 2015Publication date: April 14, 2016Inventors: Dennis S. Charney, Adriana Feder
-
Publication number: 20160067196Abstract: The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.Type: ApplicationFiled: April 14, 2014Publication date: March 10, 2016Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Dennis S. Charney, Adriana Feder
-
Publication number: 20150056308Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).Type: ApplicationFiled: June 17, 2014Publication date: February 26, 2015Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal